
Regional Health Properties, Inc. | 10-Q: FY2025 Q1 Revenue: USD 7.19 M

I'm PortAI, I can summarize articles.
Revenue: As of FY2025 Q1, the actual value is USD 7.19 M.
EPS: As of FY2025 Q1, the actual value is USD -0.94.
EBIT: As of FY2025 Q1, the actual value is USD -185 K.
Real Estate Services Segment
- Rental Revenues: $1.548 million for the three months ended March 31, 2025, compared to $1.818 million for the same period in 2024, representing a decrease of 14.9%.
- Expenses: Facility rent expense was $0.149 million, and depreciation and amortization were $0.324 million for the three months ended March 31, 2025.
- Loss on Lease Termination: $0.303 million for the three months ended March 31, 2025.
- Operating Loss: - $249 thousand for the three months ended March 31, 2025.
Healthcare Services Segment
- Patient Care Revenues: $5.642 million for the three months ended March 31, 2025, compared to $2.309 million for the same period in 2024, representing an increase of 144.3%.
- Expenses: Patient care expense was $4.401 million, and general and administrative expenses were $1.210 million for the three months ended March 31, 2025.
- Operating Loss: - $69 thousand for the three months ended March 31, 2025.
Cash Flow
- Net Cash Provided by Operating Activities: $0.236 million for the three months ended March 31, 2025, compared to $0.597 million for the same period in 2024.
- Net Cash Used in Investing Activities: - $65 thousand for the three months ended March 31, 2025.
- Net Cash Used in Financing Activities: - $587 thousand for the three months ended March 31, 2025.
Future Outlook and Strategy
- Core Business Focus: The company plans to grow operations, streamline cost infrastructure, and increase liquidity through refinancing or repaying debt, increasing lease revenue, modifying lease terms, replacing defaulting tenants, and reducing expenses.
- Non-Core Business: The company is involved in a merger agreement with SunLink Health Systems, Inc., which includes the issuance of new shares and preferred stock, subject to shareholder and regulatory approvals.

